Every 8-K that Lucid Diagnostics Inc. (LUCD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LUCD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LUCD filings page.
Lucid Diagnostics Inc. (LUCD) reports progress in payment, billing, and coding pathways for its EsoGuard Esophageal DNA Test and EsoCheck cell collection device. A Medicare Advisory Panel recommended maintaining EsoGuard’s original gapfill payment basis under the Clinical Laboratory Fee Schedule, with final CMS determinations expected in November after public comment.
The AMA CPT Editorial Panel approved a new Category III CPT code for nonendoscopic esophageal cell collection procedures performed with EsoCheck, enabling reporting and tracking once effective. The CDC/NCHS ICD-10 Coordination and Maintenance Committee gave a favorable response to a proposed new diagnosis code R85.83 for positive EsoGuard results, which the company expects to be finalized after public comment. Lucid will begin submitting Medicare claims under PLA code 0114U this month for tests at its Texas laboratory and after a revised Local Coverage Determination is effective for its California laboratory.
Lucid Diagnostics Inc. reported second quarter 2026 results and a business update focused on its EsoGuard esophageal DNA test. The company recognized $1.5 million in EsoGuard revenue and processed 2,770 EsoGuard tests in the quarter. Management highlighted securing a commercial coverage policy through Concert, recently acquired by Lyric, which deems EsoGuard medically necessary for eligible patients and has been adopted by multiple client health plans, as well as progress with the VA and major health systems.
For the three months ended June 30, 2026, operating expenses were about $14.3 million, including $1.7 million of stock-based compensation. GAAP net loss was approximately $11.7 million, and net loss attributable to common stockholders was about $14.7 million, or $(0.08) per share. Non-GAAP adjusted loss was about $10.9 million, or $(0.06) per share. Cash and cash equivalents were $33.4 million as of June 30, 2026, compared with $34.7 million as of December 31, 2025.
Lucid Diagnostics Inc. reported results of its annual stockholder meeting, where about 84.7% of shares entitled to vote were represented. Stockholders re-elected three Class B directors, approved an increase in authorized common shares, and ratified the company’s independent auditor.
Authorized common stock rose by 100,000,000 shares, from 300,000,000 to 400,000,000, through an amendment to the certificate of incorporation that became effective upon filing with the Delaware Secretary of State. Stockholders also ratified CBIZ CPAs P.C. as independent registered public accounting firm for the year ending December 31, 2025.
Lucid Diagnostics Inc. reported first-quarter 2026 results and a business update centered on its EsoGuard esophageal DNA test. The company processed 3,177 EsoGuard tests and generated $1.3 million in EsoGuard revenue for the quarter.
GAAP net loss was approximately $13.9 million, or $(0.17) per common share, including a deemed Preferred Stock dividend that brought net loss attributable to common stockholders to about $23.6 million. Non-GAAP adjusted loss was roughly $10.5 million, or $(0.07) per share.
Lucid ended March 31, 2026 with $27.9 million in cash and cash equivalents and had recently completed an underwritten public offering of common stock, netting about $17 million, resulting in $45 million in proforma cash and a runway extending into 2027. Management emphasized progress toward Medicare coverage, growing EsoGuard demand, and broader engagement with health systems, the VA, and commercial payors.
Lucid Diagnostics Inc. closed an underwritten public offering of 18,000,000 shares of common stock at $1.00 per share, raising gross proceeds of approximately $18 million. Net proceeds are expected to be about $16.8 million after underwriting discounts and expenses.
The company plans to use the net proceeds for working capital and general corporate purposes, helping fund its commercial-stage cancer prevention diagnostics business. The offering was made under an effective shelf registration statement on Form S-3, with Canaccord Genuity LLC and BTIG, LLC acting as joint bookrunners.
Lucid Diagnostics Inc. is raising $18,000,000 through an underwritten public offering of 18,000,000 common shares at a public offering price of $1.00 per share. Underwriters will purchase the shares at $0.94 per share, reflecting a $0.06 per-share underwriting discount, and will be reimbursed for certain expenses up to $75,000.
The company expects the sale to close on or about April 24, 2026, subject to customary conditions, with Canaccord Genuity and BTIG acting as joint bookrunners. The offering is made from Lucid’s effective Form S-3 shelf registration, and a related press release notes that the company intends to use net proceeds for working capital and general corporate purposes.
Lucid Diagnostics Inc. reported fourth quarter and full-year 2025 results and provided a business update centered on its EsoGuard esophageal DNA test. In 4Q25 the company processed 3,664 EsoGuard tests and generated $1.5 million in revenue.
For the quarter, operating expenses were $15.5 million and GAAP net loss attributable to common stockholders was about $16.3 million, or $(0.12) per share. Non-GAAP adjusted loss was $12.6 million, or $(0.10) per share.
For full-year 2025, revenue was $4.7 million and GAAP net loss was $58.0 million. Lucid ended 2025 with $34.7 million in cash and cash equivalents, compared with $22.4 million a year earlier.
The company highlighted a U.S. Department of Veterans Affairs contract that provides Medicare-aligned pricing of $1,938 per EsoGuard test across approximately 170 VA medical centers, and positive real-world data in nearly 12,000 at-risk patients showing a 95% technical success rate for its EsoCheck collection device.
Lucid Diagnostics (LUCD) furnished an update announcing it issued a press release with financial results for the fiscal quarter ended September 30, 2025 and a business update. The release was provided as Exhibit 99.1. The information was furnished under Items 2.02 and 7.01 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference unless specifically stated.
Lucid Diagnostics Inc. disclosed that under the agreements governing the sale of its Convertible Notes, the note holders have the collective right to designate one individual to be appointed to the company’s board of directors. This appointment right is subject to certain limitations and to the policies and procedures of the company’s nominating and corporate governance committee. The filing text is brief and focuses solely on the governance right tied to the Convertible Notes.
Lucid Diagnostics, Inc. disclosed a material event on a Form 8-K filed on September 11, 2025. The filing references a preliminary prospectus supplement dated September 9, 2025 and a final prospectus supplement dated September 10, 2025, and attaches a press release announcing the closing as Exhibit 99.1. The document is signed by Dennis McGrath, Chief Financial Officer. The filing indicates a Regulation FD disclosure checkbox and an Inline XBRL cover page data file are included.
The short filing confirms paperwork and a press release related to a completed transaction or offering, but it does not disclose financial terms, the size of any offering, counterparties, or operational impacts. The available content documents the administrative close and supporting prospectus supplements without quantitative details.
Lucid Diagnostics entered into an underwriting agreement to sell common stock to the public at $1.00 per share, with the underwriters purchasing shares from the company at $0.9425 per share, representing a $0.0575 underwriting discount. The company granted the underwriters a 30-day option to buy up to 3,750,000 additional shares at the public offering price less the underwriting discount. Lucid agreed to reimburse certain underwriting expenses, including legal fees, up to $100,000, and to indemnify the underwriters for specified liabilities under the Securities Act.
The filing cites an underlying registration statement originally filed on November 25, 2022 and declared effective December 6, 2022, and notes a preliminary prospectus supplement dated September 9, 2025 filed that same day; a final prospectus supplement will be filed under Rule 424. The Underwriting Agreement is subject to customary closing conditions, representations, warranties and covenants.
Lucid Diagnostics Inc. announced it furnished a press release reporting financial results and a business update for the fiscal quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into this Form 8-K. The company disclosed that the information under Items 2.02 and 7.01, including the exhibit, is furnished and shall not be deemed "filed" under the Exchange Act for purposes of Section 18, nor incorporated by reference in other filings except by specific reference. The filing identifies the registrant as Lucid Diagnostics Inc., trading as LUCD on The Nasdaq Stock Market, and indicates the company qualifies as an emerging growth company.